| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 3 | +66.67% | +3.61% | -0.77% | +4.38% | +1.28% | — |
| 14d | 3 | +33.33% | +5.90% | -0.39% | +6.29% | +3.75% | — |
| 30d | 3 | +0.00% | +3.79% | -3.11% | +6.90% | +5.55% | — |
| 60d | 3 | +0.00% | +46.95% | -7.73% | +54.68% | +16.26% | — |
| 90d | 3 | +0.00% | +35.48% | +1.76% | +33.71% | +65.97% | — |
| 180d | 3(2 pending) | +0.00% | -34.72% | +3.88% | -38.60% | -38.60% | — |
| 1y | 3(2 pending) | +100.00% | +10.65% | +14.25% | -3.60% | -3.60% | — |
| 2y | 3(3 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| ZNTL ZENTALIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 335 | $2.39 | $802 | 33,332 | Feb 9, 2026 | Feb 10, 2026 ↗ | View → |
| ZNTL ZENTALIS PHARMACEUTICALS, INC. | SALE Chief Medical Officer | 2,962 | $2.43 | $7.2K | 33,667 | Feb 6, 2026 | Feb 10, 2026 ↗ | View → |
| ZNTL ZENTALIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 365,000 | — | — | 365,000 | Jan 8, 2026 | Jan 9, 2026 ↗ | View → |
| ZNTL ZENTALIS PHARMACEUTICALS, INC. | PURCHASE Chief Medical Officer | 20,000 | $2.28 | $45.7K | 36,629 | Feb 6, 2025 | Feb 12, 2025 ↗ | View → |
| ZNTL ZENTALIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 16,629 | — | — | 16,629 | Feb 3, 2025 | Feb 5, 2025 ↗ | View → |
| ZNTL ZENTALIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 16,629 | — | — | 16,629 | Feb 3, 2025 | Feb 5, 2025 ↗ | View → |
| ZNTL ZENTALIS PHARMACEUTICALS, INC. | PURCHASEGRANT Stock grant | 712,650 | — | — | 712,650 | Dec 2, 2024 | Dec 3, 2024 ↗ | View → |